Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624634 | 0.86 | HTR6 (0.51) | HTR6 | |
| SCHEMBL4300547 | 0.76 | HTR6 (0.53) | HTR6MEN1KMT2A | |
| SCHEMBL1898801 | 0.75 | HTR6 (0.58) | HTR6MEN1KMT2A | |
| SCHEMBL4170305 | 0.74 | MEN1 (0.50) | HTR6HTR1AHTR2AHTR7MEN1 | |
| SCHEMBL835021 | 0.72 | HTR6 (1.00) | HTR6 | |
| SCHEMBL8540570 | 0.71 | HTR6 (0.55) | HTR6 | |
| SCHEMBL3563869 | 0.69 | HTR6 (0.50) | HTR6 | |
| SCHEMBL24015624 | 0.68 | HTR6 (0.52) | HTR6 | |
| SCHEMBL12675369 | 0.68 | SRC (0.54) | HTR6MEN1KMT2A | |
| SCHEMBL3562443 | 0.68 | ACLY (0.50) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1817026-A2 | HCV INHIBITORS | SmithKline Beecham Corporation (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | SMITHKLINE BEECHAM CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006121466-A2 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1658068-A1 | NOVEL CYCLOALKYL'B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005023245-A1 | NOVEL CYCLOALKYL’B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | HTR6 4552/4885HTR1A 4178/4885HTR2A 4132/4885 |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | BCCIP, TP53, TOP2B | HTR6 567/4885HTR1A 979/4885HTR2A 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.